Plus Therapeutics
Austin, Texas, United States · Biotechnology, Health Care, Manufacturing
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes for patients. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in recurrent
Key facts
- Headquarters
- Austin, Texas, United States
- Employees
- 24
- Industries
- Biotechnology, Health Care, Manufacturing
- Status
- Public (CNSY)
- Website
- plustherapeutics.com
- Company page
Recent activity at Plus Therapeutics
- : PLUS THERAPEUTICS
- : Plus Therapeutics Appoints Eric J. Daniels as Chief Development Officer
- : SEC 8-K (1.01): On October 16, 2025, Plus Therapeutics, Inc. entered into a material definitive agreement, a lease with LG 1 Property Owner LP, for approximately 11,370 rentable square feet of office space located at 6420 Levit Green Boulevard, Houston, Texas. The lease is scheduled to commence on or about November 1, 2026, and includes a monthly base rent of $58,745, which will increase annually by approximately 3%, in addition to the company's share of direct building expenses. The lease has an initial term of 120 calendar months, indicating a long-term commitment by Plus Therapeutics to establish a physical presence in the specified location, which may have strategic implications for its operations and growth.
- : Plus Therapeutics Enters National Coverage Agreement with UnitedHealthcare for CNSide® Assay to Benefit Cancer Patients.
- : Plus Therapeutics Appoints Michael Rosol, Ph.D., as Chief Development Officer
- : Plus Therapeutics Secures $5.7 Million Financing to Support Leptomeningeal Metastases Program
- : Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership
- : Plus Therapeutics and SpectronRx Announce Radiotherapeutic Manufacturing Partnership
- : Plus Therapeutics raised up to $18 million in private placement financing
- : PLUS THERAPEUTICS, INC.
Plus Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| Sep 2026 | Seed | $3.0M |
| May 2024 | Post-IPO Equity | $18.0M |
| May 2020 | Seed | $300K |
Leadership
- Charles Huang, Vice President
- Eric J. Daniels, Chief Development Officer
- Michael Rosol, Chief Development Officer
- Marc Hedrick, President
Verified email and direct lines for Plus Therapeutics’s decision-makers are on Fundz. See plans
Employee benefit plans
Plus Therapeutics files 1 employee benefit plan with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Plus Therapeutics in the news
- Plus Therapeutics Announces Scientific Presentations and - GlobeNewswire (Jul 28, 2026)
- Plus Therapeutics Secures Regional Coverage Agreement with - GlobeNewswire (Jul 21, 2026)
- Plus Therapeutics Partners with Ephemeral Technologies to Deploy AI Execution Platform for CNS Oncology - GlobeNewswire (May 19, 2026)
- Can Radiotherapeutics and Early Detection Offer a Breakthrough for Rare CNS Cancer? - AJMC (Oct 29, 2025)
- Plus Therapeutics to Provide Business Update Call on June 30, 2026 - GlobeNewswire (Jun 23, 2026)
- Plus Therapeutics Secures National Coverage Agreement with - GlobeNewswire (Jun 25, 2026)
- Plus Therapeutics Reports First Quarter 2026 Financial - GlobeNewswire (May 15, 2026)
- Plus Therapeutics Reports 2025 Results, Business Progress - GlobeNewswire (Mar 12, 2026)
Companies similar to Plus Therapeutics
- Altro and Amici Pharmaceuticals · Biotechnology, Health Care, Manufacturing, Pharmaceutical
- WG Critical Care · Biotechnology, Health Care, Manufacturing, Pharmaceutical
- LSL Pharma Group · Biotechnology, Health Care, Manufacturing, Pharmaceutical
- Unichem Laboratories Limited · Biotechnology, Health Care, Manufacturing, Pharmaceutical
- Evariste · Biotechnology, Health Care, Manufacturing, Pharmaceutical
About Plus Therapeutics: questions and answers
What does Plus Therapeutics do?
Plus Therapeutics, Inc. is a clinical-stage pharmaceutical company developing targeted radiotherapeutics for difficult-to-treat cancers of the central nervous system with the potential to enhance clinical outcomes for patients. Combining image-guided local beta radiation and targeted drug delivery approaches, the Company is advancing a pipeline of product candidates with lead programs in recurrent
Where is Plus Therapeutics headquartered?
Plus Therapeutics is headquartered in Austin, Texas, United States.
How many employees does Plus Therapeutics have?
Plus Therapeutics has about 24 employees.
Has Plus Therapeutics raised funding?
Yes. Fundz has recorded 3 funding events for Plus Therapeutics. The most recent, Seed of $3.0M, was in Sep 2026.
Who leads Plus Therapeutics?
Charles Huang is a Vice President at Plus Therapeutics.
What is the latest news on Plus Therapeutics?
On Sep 18, 2026, PLUS THERAPEUTICS
Is Plus Therapeutics a public company?
Yes. Plus Therapeutics is publicly traded under the ticker CNSY.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy